GILD vs REGN vs AMGN Stock Comparison

Gilead Sciences, Regeneron Pharmaceuticals and Amgen Prices as of Nov 13, 2026 Peers: Industry group
GILD Gilead Sciences, Inc.
$168.08 +9.5% 1M +34.2% 1Y
Market cap
$207.56B
P/E
–
Revenue (TTM)
$30.99B
Div. yield
–
Biotechnology Healthcare
2 wins
AMGN Amgen Inc
$465.67 +9.3% 1M +38.6% 1Y
Market cap
$250.23B
P/E
26.6x
Revenue (TTM)
$38.90B
Div. yield
0.02%
Biotechnology Healthcare
3 wins

Head to Head

11 decided of 12

Regeneron Pharmaceuticals leads on 6 of the 12 questions below (Regeneron Pharmaceuticals 6, Amgen 3, Gilead Sciences 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGILDREGNAMGNLeader
Larger companyMarket capitalisation $207.56B $96.53B $250.23B AMGN
Cheaper on earningsLower P/E, profitable companies only -53.7x 20.0x 26.6x REGN
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 14.8x 20.9x REGN
Faster revenue growthRevenue growth, trailing twelve months +6.5% +18.6% +8.2% REGN
More profitableNet margin, trailing twelve months -12.5% 28.5% 24.1% REGN
Better return on capitalReturn on invested capital -6.1% 11.9% 15.6% AMGN
Less leveragedLower net debt / EBITDA 43.8x -1.4x 2.4x REGN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.02% –
Better 1-year returnPrice return, last 12 months +34.2% +37.5% +38.6% AMGN
Better 5-year returnAnnualised price return, 5 years +20.0%/yr +8.7%/yr +17.1%/yr GILD
Less volatileAnnualised volatility, 1 year 27.5% 33.9% 28.8% GILD
Higher overall scoreMean of the five percentile scores vs peers 61/100 73/100 66/100 REGN

Percentile Scorecard

GILDREGNAMGN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGILDREGNAMGN
Valuation 89 #71 of 660 89 #75 of 660 85 #103 of 660
Growth 34 #408 of 619 50 #308 of 619 61 #245 of 619
Profitability 85 #91 of 595 92 #48 of 595 95 #32 of 595
Financial Health 22 #530 of 683 71 #199 of 683 23 #528 of 683
Shareholder Returns 75 #116 of 459 63 #170 of 459 67 #152 of 459
Overall 61 73 66
  • GILD ranked among 695 companies in Pharmaceuticals and Biotechnology
  • REGN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • AMGN ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGILDREGNAMGNSPY
1 month +9.5%+22.8%+9.3% -2.0%
3 months +21.5%+18.9%+12.2% -2.8%
6 months +29.7%+36.8%+42.7% +2.0%
Year to date +36.9%+23.8%+42.3% +10.6%
1 year +34.2%+37.5%+38.6% +12.2%
3 years +124.9%+20.4%+72.5% +68.1%
3 years, per year +31.1%+6.4%+19.9% +18.9%
5 years +149.1%+51.4%+120.3% +61.4%
5 years, per year +20.0%+8.7%+17.1% +10.1%
10 years +119.9%+127.6%+212.4% +248.5%
10 years, per year +8.2%+8.6%+12.1% +13.3%

Risk

MeasureGILDREGNAMGNSPY
Volatility, 1Y 27.5%33.9%28.8% 13.6%
Downside volatility, 1Y 24.0%30.8%28.4% 13.9%
Beta vs S&P 500, 1Y 0.390.350.49 1.00
Return / volatility, 1Y 1.251.111.34 0.90
Max drawdown, 5Y -29.4%-59.8%-26.7% -25.4%
From 52-week high -3.7%-1.8%-2.7% -3.2%
52-week high $174.48$973.36$478.48 $779.14
52-week low $118.30$600.66$313.85 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGILDREGNAMGN
P/E now vs peer median -54.0xmedian 17.0x 20.2xmedian 17.0x 26.8xmedian 17.0x
P/S now vs peer median 6.7xmedian 8.4x 5.8xmedian 8.4x 6.5xmedian 8.4x
EV/EBITDA now vs peer median 505.3xmedian 14.6x 16.7xmedian 14.6x 17.1xmedian 14.6x
P/FCF now vs peer median 15.1xmedian 19.0x 25.4xmedian 19.0x 26.3xmedian 19.0x
P/B now vs peer median 16.0xmedian 2.0x 2.9xmedian 2.0x 17.6xmedian 2.0x
PEG now vs peer median 1.40median 0.43 2.23median 0.43 3.86median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGILDREGNAMGN
Revenue $30.99B $16.90B $38.90B
Gross profit $24.77B $14.49B $27.58B
Operating income -$2.36B $4.86B $12.61B
Net income -$3.86B $4.82B $9.39B
Free cash flow $13.78B $3.83B $9.58B
R&D $6.33B $6.60B $7.84B
EPS (diluted) $-3.09 $45.62 $17.20
Cash & equivalents $6.44B $3.66B $13.19B
Total debt $26.23B $1.99B $54.01B
Shares (diluted) 1.25B 105.60M 546.00M
Enterprise value $182.67B $61.88B $201.89B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGILDREGNAMGN
P/E -54.0x 20.2x 26.8x
P/FCF 15.1x 25.4x 26.3x
P/Operating cash flow 14.4x 20.1x 20.9x
P/S 6.7x 5.8x 6.5x
P/B 16.0x 2.9x 17.6x
P/Tangible book -543.2x 3.0x -48.6x
EV/EBITDA 505.3x 16.7x 17.1x
EV/EBIT -96.7x 18.5x 23.2x
EV/Revenue 7.4x 5.3x 7.5x
EV/FCF 16.6x 23.5x 30.5x
EV/Operating cash flow 15.8x 18.5x 24.3x
PEG (3Y EPS CAGR) 1.40 2.23 3.86

Growth

14 metrics
MetricGILDREGNAMGN
Revenue growth (1Y) 6.5% 18.6% 8.2%
Revenue CAGR (3Y) 4.2% 8.9% 13.2%
Gross profit growth (1Y) 8.2% 19.1% 15.9%
Gross profit CAGR (3Y) 4.7% 8.8% 11.8%
Operating income growth (1Y) -122.5% 31.9% 45.4%
Operating income CAGR (3Y) -31.7% 4.8% 12.5%
Net income growth (1Y) -147.6% 5.2% 34.1%
Net income CAGR (3Y) -38.5% 6.5% 7.5%
EPS growth (1Y) -147.7% 6.8% 33.1%
EPS CAGR (3Y) -38.6% 9.0% 6.9%
Operating cash flow growth (1Y) 49.8% -4.4% -8.3%
Operating cash flow CAGR (3Y) 19.9% -2.5% 4.4%
Free cash flow growth (1Y) 50.4% -9.4% -17.0%
Free cash flow CAGR (3Y) 20.6% -6.0% 0.7%

Profitability

14 metrics
MetricGILDREGNAMGN
Gross margin 79.9% 85.8% 70.9%
EBITDA margin 1.5% 31.8% 43.9%
Operating margin -7.6% 28.8% 32.4%
Pretax margin -8.2% 33.7% 28.4%
Net margin -12.5% 28.5% 24.1%
FCF margin 44.5% 22.6% 24.6%
Operating cash flow margin 46.7% 28.7% 30.9%
Return on equity -31.2% 14.0% 72.1%
Return on assets -7.7% 10.6% 9.8%
Return on invested capital -6.1% 11.9% 15.6%
Return on capital employed -6.2% 13.2% 17.4%
Asset turnover 0.6x 0.4x 0.4x
Cash conversion (OCF / net income) -3.7x 1.0x 1.3x
Stock comp / revenue 2.9% 6.0% 1.3%

Financial Health

11 metrics
MetricGILDREGNAMGN
Debt / assets 51.0% 4.5% 56.2%
Debt / equity 2.0x 0.1x 3.8x
Net debt / EBITDA 43.8x -1.4x 2.4x
Debt / FCF 1.9x 0.5x 5.6x
Liabilities / assets 74.6% 24.6% 85.1%
Equity / assets 25.4% 75.4% 14.9%
Interest coverage -2.3x 104.2x 4.8x
Current ratio 1.4x 3.4x 1.5x
Quick ratio 1.0x 2.7x 1.0x
Cash ratio 0.5x 1.5x 0.6x
Altman Z-score 3.90 7.73 2.54

Shareholder Returns

7 metrics
MetricGILDREGNAMGN
Dividend yield 1.9% 0.4% 2.1%
Net buyback yield 0.5% 2.1% –
Shareholder yield 2.5% 2.5% 2.1%
Payout ratio (earnings) – – 57.1%
Payout ratio (FCF) – – 56.0%
Dividend growth (1Y) – – 6.3%
Dividend CAGR (3Y) – – 6.4%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGILDREGNAMGN
Forward P/E – 14.8xFY2026 20.9xFY2026
EPS, next fiscal year $-0.84FY2026 $64.62FY2026 $22.28FY2026
EPS growth, next FY -110.3%FY2026 +45.8%FY2026 +2.0%FY2026
EPS growth, the year after – +13.6% +7.2%
Revenue, next fiscal year $29.15BFY2026 $18.08BFY2026 $42.01BFY2026
Revenue growth, next FY -1.0%FY2026 +26.1%FY2026 +14.3%FY2026
Revenue growth, the year after +18.3% +14.6% +3.1%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGILDREGNAMGN
Held by institutions 89.6% 66.2% 82.7%
Institutions holding 2,293 1,329 3,163
Change in shares held, QoQ +5.1% +3.8% +4.5%
Institutions buying 1,113 607 1,452
Institutions selling 853 534 1,219
Buyers to sellers 1.30 1.14 1.19

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GILDREGNAMGN
GILD 1.00 0.42 0.57
REGN 0.42 1.00 0.46
AMGN 0.57 0.46 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GILD, REGN and AMGN?

Amgen (AMGN) is the largest by market capitalisation: Gilead Sciences (GILD) $207.56B, Regeneron Pharmaceuticals (REGN) $96.53B, Amgen (AMGN) $250.23B.

Which stock is cheaper, GILD, REGN and AMGN?

Regeneron Pharmaceuticals (REGN) trades on the lowest price-to-earnings ratio (Gilead Sciences (GILD) -53.7x, Regeneron Pharmaceuticals (REGN) 20.0x, Amgen (AMGN) 26.6x). On next year's consensus earnings, Regeneron Pharmaceuticals (REGN) is cheapest (Regeneron Pharmaceuticals (REGN) 14.8x, Amgen (AMGN) 20.9x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Regeneron Pharmaceuticals (REGN) grew revenue fastest over the trailing twelve months: Gilead Sciences (GILD) +6.5%, Regeneron Pharmaceuticals (REGN) +18.6%, Amgen (AMGN) +8.2%.

Which company is more profitable?

Regeneron Pharmaceuticals (REGN) has the highest net margin (Gilead Sciences (GILD) -12.5%, Regeneron Pharmaceuticals (REGN) 28.5%, Amgen (AMGN) 24.1%). On return on invested capital, Amgen (AMGN) leads (Gilead Sciences (GILD) -6.1%, Regeneron Pharmaceuticals (REGN) 11.9%, Amgen (AMGN) 15.6%).

Which stock has performed better?

Over the past year Amgen (AMGN) returned the most: Gilead Sciences (GILD) +34.2%, Regeneron Pharmaceuticals (REGN) +37.5%, Amgen (AMGN) +38.6%. Over five years, Gilead Sciences (GILD) compounded fastest (Gilead Sciences (GILD) +20.0%/yr, Regeneron Pharmaceuticals (REGN) +8.7%/yr, Amgen (AMGN) +17.1%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Gilead Sciences (GILD) 0.00%, Regeneron Pharmaceuticals (REGN) 0.00%, Amgen (AMGN) 0.02%. Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Gilead Sciences (GILD) has been the steadiest (Gilead Sciences (GILD) 27.5%, Regeneron Pharmaceuticals (REGN) 33.9%, Amgen (AMGN) 28.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GILD, REGN and AMGN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Regeneron Pharmaceuticals (REGN) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.